Global Regulatory Intelligence
Log in |  Register

Login to your account

Username *
Password *
Remember Me

Create an account

Registering to our Regulatory Updates easy andis should only
take few minutes. To begin, enter your email enter your email
address below so we can check to see if it is already existing
in our records. Your email address will also be used as your
user name when you log in.

Fields marked with an asterisk (*) are required.
Name *
Username *
Password *
Verify password *
Email *
Verify email *
Captcha *
Reload Captcha

USA: FDA Finalizes Guidance on Co-Crystals in NDAs and ANDAs

Wednesday, February 14, 2018: The US Food and Drug Administration (FDA) released a final guidance titled “Regulatory Classification of Pharmaceutical Co-Crystals Guidance for Industry.” The guidance provides information about the regulatory classification of pharmaceutical co-crystal solid-state forms, the data that applicants should submit to support the appropriate classification, and the regulatory implications of the classification.

The guidance describes co-crystals as “crystalline materials composed of two or more different molecules, typically active pharmaceutical ingredient (API) and co-crystal formers (‘coformers’), in the same crystal lattice.” Co-crystals provide a means to develop solid-state forms of an API beyond conventional solid-state forms, such as salts and polymorphs. Co-crystals can also be developed to enhance bioavailability, stability, and processability of APIs.

According to the guidance, co-crystals differ from both salts and polymorphs, and are more akin to solvates, since both solvates and co-crystals have multiple components in their crystal lattices. Thus, NDAs and ANDAs containing or claiming to contain a co-crystal form should include appropriate data supporting the classification of a co-crystal. In particular, applicants should provide evidence to demonstrate that:

  • both the API and coformers are present in the unit cell;
  • if both the API and coformer have ionizable functional groups, the component API and coformer co-exist in the co-crystal and interact nonionically (the guidance provides a general guideline based on the ΔpKa between the API and its coformer); and
  • substantial dissociation of the API from its co-crystal form occurs before reaching the site of pharmacological activity.

A co-crystal with a pharmaceutically acceptable coformer that meets the above conditions can be considered to be a pharmaceutical co-crystal. The guidance notes that such co-crystals have a regulatory classification similar to that of a polymorph of the API, and are not regarded as a new API. In addition, a co-crystal that is composed of two or more APIs (with or without additional inactive coformers) will be treated as a fixed-dose combination product, and not as a new single API.

More Details
© 2016 MakroCare. All Rights Reserved.
  Privacy policy